v3.26.1
Income taxes recognized in the income statement (Tables) - Veraxa Biotech A G [Member]
12 Months Ended
Dec. 31, 2025
Entity Information [Line Items]  
Schedule of operating activities
               
    For the
Years Ended
December 31,
 
in CHF   2025     2024  
Current taxes                
Income tax income/expense in the current financial year   -     -  
                 
Deferred taxes                
Recognized deferred (tax expense)/tax income     392,603       620,774  
Reported tax income for the current period   392,603     620,774  
Schedule of tax expense income for the financial year
           
in CHF   December 31,
2025
    December 31,
2024
 
Earnings before income taxes   (67,006,593 )   (28,753,745 )
Income tax expense at a tax rate of 31%   20,772,044     8,913,661  
Amortization of deferred tax assets due to derecognition     -       -  
Effects of non-tax-deductible expenses and income     (12,336,984 )     (5,420,625 )
Effects of results for which no deferred taxes were recognized     (7,523,688 )     (2,666,379 )
Effects of losses for which deferred tax assets were recognized     -       -  
Tax rate differences     (428,768 )     (205,883 )
Tax amount recognized in the income statement   482,603     620,774